Analysts Anticipate Synlogic Inc (SYBX) to Post -$0.78 Earnings Per Share
Equities research analysts expect that Synlogic Inc (NASDAQ:SYBX) will report earnings per share of ($0.78) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Synlogic’s earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.76). Synlogic reported earnings of ($2.94) per share in the same quarter last year, which suggests a positive year over year growth rate of 73.5%. The business is scheduled to announce its next quarterly earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Synlogic will report full year earnings of ($5.42) per share for the current financial year, with EPS estimates ranging from ($5.58) to ($5.26). For the next financial year, analysts expect that the company will post earnings of ($2.76) per share, with EPS estimates ranging from ($3.35) to ($2.16). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Synlogic.
A number of brokerages have weighed in on SYBX. Leerink Swann began coverage on shares of Synlogic in a research note on Tuesday, September 19th. They set an “outperform” rating and a $25.00 target price for the company. Wedbush began coverage on shares of Synlogic in a research note on Monday, November 27th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. Synlogic has a consensus rating of “Hold” and an average price target of $19.67.
WARNING: “Analysts Anticipate Synlogic Inc (SYBX) to Post -$0.78 Earnings Per Share” was reported by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/29/analysts-anticipate-synlogic-inc-sybx-to-post-0-78-earnings-per-share-updated-updated-updated.html.
Synlogic Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.